Reuters logo
a year ago
BRIEF-Aveo Pharmaceuticals announces dosing of first patient in Phase 3 tivo-3 study of tivozanib in renal cell carcinoma
May 26, 2016 / 12:17 PM / a year ago

BRIEF-Aveo Pharmaceuticals announces dosing of first patient in Phase 3 tivo-3 study of tivozanib in renal cell carcinoma

May 26 (Reuters) - Aveo Pharmaceuticals Inc

* Announces dosing of first patient in pivotal Phase 3 tivo 3 study of tivozanib in renal cell carcinoma

* Top line readout of study is currently projected for Q1 of 2018 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below